English
Back
Download
Log in to access Online Inquiry
Back to the Top
avatar
Jaguar8 commented on a stock · Jul 11, 2024 20:00

NEWS

Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and online from July 28 to August 1, 2024. Sabirnetug, a humanized monoclonal antibody, has shown selective target engagement of toxic soluble amyloid beta oligomers (AβOs) in early symptomatic Alzheimer's disease (AD) patients. The company’s posters will discuss biomarker data, methods for detecting sabirnetug levels in cerebrospinal fluid (CSF), and patient experiences. The data aims to inform future clinical trials and potentially position sabirnetug as a best-in-class antibody treatment for early symptomatic AD.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
6502 Views
Comment
Sign in to post a comment
    avatar
    Jaguar8
    Spread kindness and love. Life is short. Don’t let greed eat you.
    9165
    Followers
    54
    Following
    110K
    Visitors
    Follow
    Heat List
    US
    SymbolMini ChartPrice
    NVDA
    NVIDIA
    -- 115.430
    TSLA
    Tesla
    -- 225.310
    INTC
    Intel
    -- 25.920
    PLTR
    Palantir
    -- 83.890
    BABA
    Alibaba
    -- 142.740
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.